<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39356899</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2965-2774</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Critical care science</Title><ISOAbbreviation>Crit Care Sci</ISOAbbreviation></Journal><ArticleTitle>Advancing insights in critical COVID-19: unraveling lymphopenia through propensity score matching - Findings from the Multicenter LYMPH-COVID Study.</ArticleTitle><Pagination><StartPage>e20240236en</StartPage><MedlinePgn>e20240236en</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e20240236en</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.62675/2965-2774.20240236-en</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2965-27742024000100316</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To elucidate the impact of lymphopenia on critical COVID-19 patient outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicenter prospective cohort study across five hospitals in Portugal and Brazil from 2020 to 2021. The study included adult patients admitted to the intensive care unit with SARS-CoV-2 pneumonia. Patients were categorized into two groups based on their lymphocyte counts within 48 hours of intensive care unit admission: the Lymphopenia Group (lymphocyte serum count &lt; 1 × 109/L) and the Nonlymphopenia Group. Multivariate logistic regression, propensity score matching, Kaplan‒Meier survival curve analysis and Cox proportional hazards regression analysis were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 912 patients were enrolled, with 191 (20.9%) in the Nonlymphopenia Group and 721 (79.1%) in the Lymphopenia Group. Lymphopenia patients displayed significantly elevated disease severity indices, including Sequential Organ Failure Assessment and Simplified Acute Physiology Score 3 scores, at intensive care unit admission (p = 0.001 and p &lt; 0.001, respectively). Additionally, they presented heightened requirements for vasopressor support (p = 0.045) and prolonged intensive care unit and in-hospital stays (both p &lt; 0.001). Multivariate logistic regression analysis after propensity score matching revealed a significant contribution of lymphopenia to mortality, with an odds ratio of 1,621 (95%CI: 1,275 - 2,048; p &lt; 0.001). Interaction models revealed an increase of 8% in mortality for each decade of longevity in patients with concomitant lymphopenia. In the subanalysis utilizing three-group stratification, the Severe Lymphopenia Group had the highest mortality rate, not only in direct comparisons but also in Kaplan‒Meier survival analysis (log-rank test p = 0.0048).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lymphopenia in COVID-19 patients is associated with increased disease severity and an increased risk of mortality, underscoring the need for prompt support for critically ill high-risk patients. These findings offer important insights into improving patient care strategies for COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cidade</LastName><ForeName>José Pedro</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-8359-5171</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit 4, Department of Intensive Care, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental - Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza-Dantas</LastName><ForeName>Vicente Cês</ForeName><Initials>VC</Initials><Identifier Source="ORCID">0000-0002-1865-1704</Identifier><AffiliationInfo><Affiliation>Instituto D'Or de Pesquisa e Ensino - Rio de Janeiro (RJ), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamfrim</LastName><ForeName>Rafaela Braga</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Hospital Copa D'Or - Rio de Janeiro (RJ), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Renata Carnevale</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Hospital Copa D'Or - Rio de Janeiro (RJ), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caroli</LastName><ForeName>Henrique Tommasi</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Hospital Copa D'Or - Rio de Janeiro (RJ), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Natália Almeida</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Hospital Copa D'Or - Rio de Janeiro (RJ), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alessandra Figueiredo</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-9669-9391</Identifier><AffiliationInfo><Affiliation>Hospital Copa D'Or - Rio de Janeiro (RJ), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Gabriela E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Hospital Copa D'Or - Rio de Janeiro (RJ), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Póvoa</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7069-7304</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit 4, Department of Intensive Care, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental - Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Crit Care Sci</MedlineTA><NlmUniqueID>9918627781706676</NlmUniqueID><ISSNLinking>2965-2774</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="Y">Lymphopenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="Y">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011174" MajorTopicYN="N" Type="Geographic">Portugal</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="OBJETIVO">Elucidar o impacto da linfopenia nos desfechos críticos de pacientes com COVID-19.</AbstractText><AbstractText Label="MÉTODOS">Trata-se de estudo de coorte prospectivo multicêntrico realizado em cinco hospitais de Portugal e do Brasil entre 2020 e 2021. O estudo incluiu pacientes adultos internados na unidade de terapia intensiva com pneumonia por SARS-CoV-2. Os pacientes foram categorizados em dois grupos com base em suas contagens de linfócitos dentro de 48 horas da admissão na unidade de terapia intensiva: o Grupo Linfopenia (contagem sérica de linfócitos &lt; 1 × 10<sup>9</sup>/L) e o Grupo sem Linfopenia. Foram utilizadas regressão logística multivariada, correspondência de escore de propensão, análise da curva de sobrevida de Kaplan-Meier e análise de regressão de riscos proporcionais de Cox.</AbstractText><AbstractText Label="RESULTADOS">Participaram 912 pacientes, sendo 191 (20,9%) no Grupo sem Linfopenia e 721 (79,1%) no Grupo com Linfopenia. Os pacientes com linfopenia apresentaram índices de gravidade da doença significativamente elevados, incluindo a <i>Sequential Organ Failure Assessment</i> e o <i>Simplified Acute Physiology Score 3</i> , na admissão na unidade de terapia intensiva (p = 0,001 e p &lt; 0,001, respectivamente). Além disso, eles apresentaram maior necessidade de suporte vasopressor (p = 0,045) e internações prolongadas na unidade de terapia intensiva e no hospital (ambos p &lt; 0,001). A análise de regressão logística multivariada após a correspondência da pontuação de propensão revelou significativa contribuição da linfopenia para a mortalidade, com razão de chances de 1.621 (IC95% 1.275 - 2.048; p &lt; 0,001). Os modelos de interação revelaram aumento de 8% na mortalidade para cada década de longevidade em pacientes com linfopenia concomitante. Na subanálise que utilizou a estratificação em três grupos, o Grupo com Linfopenia grave apresentou a maior taxa de mortalidade, não apenas em comparações diretas, mas também na análise de sobrevida de Kaplan-Meier (teste <i>log-rank</i> p = 0,0048).</AbstractText><AbstractText Label="CONCLUSÃO">A linfopenia em pacientes com COVID-19 está associada ao aumento da gravidade da doença e ao aumento do risco de mortalidade, ressaltando a necessidade de suporte imediato para pacientes críticos de alto risco. Esses achados oferecem informações importantes para melhorar as estratégias de assistência a pacientes com COVID-19.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39356899</ArticleId><ArticleId IdType="pmc">PMC11463993</ArticleId><ArticleId IdType="doi">10.62675/2965-2774.20240236-en</ArticleId><ArticleId IdType="pii">S2965-27742024000100316</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: what it shows and what can be learned. Immunol Lett . 2020;225:31–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305732</ArticleId><ArticleId IdType="pubmed">32569607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghizlane EA, Manal M, Abderrahim EK, Abdelilah E, Mohammed M, Rajae A, et al. Lymphopenia in Covid-19: a single center retrospective study of 589 cases. 102816 Ann Med Surg (Lond) . 2021;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423773</ArticleId><ArticleId IdType="pubmed">34512964</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu J, Sareli C, Mayer D, Visbal A, Sareli A. Lymphopenia as a Predictor for adverse clinical outcomes in hospitalized patients with COVID-19: a single center retrospective study of 4485 cases. 700 J Clin Med . 2022;11(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837002</ArticleId><ArticleId IdType="pubmed">35160150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. 33 Signal Transduct Target Ther . 2020;5(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100419</ArticleId><ArticleId IdType="pubmed">32296069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis . 2020;96:131–135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196544</ArticleId><ArticleId IdType="pubmed">32376308</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. 36 J Intensive Care . 2020;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245646</ArticleId><ArticleId IdType="pubmed">32483488</ArticleId></ArticleIdList></Reference><Reference><Citation>Delshad M, Tavakolinia N, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, Bagheri N, Bashash D. The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. 107586 Int Immunopharmacol . 2021;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7969831</ArticleId><ArticleId IdType="pubmed">33765611</ArticleId></ArticleIdList></Reference><Reference><Citation>Baïsse A, Daix T, Hernandez Padilla AC, Jeannet R, Barraud O, Dalmay F, et al. High prevalence of infections in non-COVID-19 patients admitted to the Emergency Department with severe lymphopenia. 295 BMC Infect Dis . 2022;22(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8960225</ArticleId><ArticleId IdType="pubmed">35346082</ArticleId></ArticleIdList></Reference><Reference><Citation>Charostad J, Rezaei Zadeh Rukerd M, Shahrokhi A, Aghda FA, Ghelmani Y, Pourzand P, et al. Evaluation of hematological parameters alterations in different waves of COVID-19 pandemic: a cross-sectional study. PLoS One . 2023;18(8):e0290242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10456189</ArticleId><ArticleId IdType="pubmed">37624800</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med . 2021;26(3):107–108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7493072</ArticleId><ArticleId IdType="pubmed">32934000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao YC, Shen PY, Wong LT, Chan MC, Chao WC. The association between absolute lymphocyte count and long-term mortality in critically ill medical patients: propensity score-based analyses. Int J Gen Med . 2023;16:3665–3675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10460208</ArticleId><ArticleId IdType="pubmed">37637708</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B, Cheruiyot I, Vikse J, Mutua V, Kipkorir V, Benoit J, et al. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis. Acta Biomed . 2020;91(3):e2020008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716963</ArticleId><ArticleId IdType="pubmed">32921706</ArticleId></ArticleIdList></Reference><Reference><Citation>Peñaloza HF, Lee JS, Ray P. Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease. PLoS Pathog . 2021;17(9):e1009850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412274</ArticleId><ArticleId IdType="pubmed">34473802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaboli E, Majidi H, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Asgarian-Omran H, Vahedi Larijani L, et al. Lymphopenia and lung complications in patients with coronavirus disease-2019 (COVID-19): A retrospective study based on clinical data. J Med Virol . 2021;93(9):5425–5431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242774</ArticleId><ArticleId IdType="pubmed">33945642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Salvati L, Maggi L, Annunziato F, Cosmi L. Hallmarks of immune response in COVID-19: exploring dysregulation and exhaustion. 101508 Semin Immunol . 2021;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547971</ArticleId><ArticleId IdType="pubmed">34728121</ArticleId></ArticleIdList></Reference><Reference><Citation>Toori KU, Qureshi MA, Chaudhry A. Lymphopenia: a useful predictor of COVID-19 disease severity and mortality. Pak J Med Sci . 2021;37(7):1984–1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613069</ArticleId><ArticleId IdType="pubmed">34912430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei J, Fu L, Li Y, Xiang HX, Xiang Y, Li MD, et al. Reduction of lymphocyte count at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study. Arch Med Sci . 2023;19(5):1303–1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10507779</ArticleId><ArticleId IdType="pubmed">37732034</ArticleId></ArticleIdList></Reference><Reference><Citation>Znegui T, Sahnoun I, Moussa I, Sassi SB, Ksouri C, Allouch A, et al. Is lymphopenia a predictive factor of outcomes in COVID-19 patients? 3922 Eur Respir J . 2022;60(Suppl 66)</Citation></Reference><Reference><Citation>Zou ZY, Ren D, Chen RL, Yu BJ, Liu Y, Huang JJ, et al. Persistent lymphopenia after diagnosis of COVID-19 predicts acute respiratory distress syndrome: a retrospective cohort study. 20587392211036825 Eur J Inflam . 2021;19</Citation></Reference><Reference><Citation>Wang X, Liu Z, Lu L, Jiang S. The putative mechanism of lymphopenia in COVID-19 patients. J Mol Cell Biol . 2022;14(5):mjac034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9412754</ArticleId><ArticleId IdType="pubmed">35641108</ArticleId></ArticleIdList></Reference><Reference><Citation>Signore A, Lauri C, Colandrea M, Di Girolamo M, Chiodo E, Grana CM, et al. Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study. Eur J Nucl Med Mol Imaging . 2022;49(10):3419–3429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050483</ArticleId><ArticleId IdType="pubmed">35486145</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Q, Feng Z, Diao B, Tu C, Qiao Q, Yang H, et al. SARS-CoV-2 Induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs. 661052 Front Immunol . 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113960</ArticleId><ArticleId IdType="pubmed">33995382</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med . 2020;26(10):1636–1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med . 2020;8(12):1233–1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>Löhr P, Schiele S, Arndt TT, Grützner S, Claus R, Römmele C, et al. Impact of age and gender on lymphocyte subset counts in patients with COVID-19. Cytometry A . 2023;103(2):127–135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426831</ArticleId><ArticleId IdType="pubmed">34125495</ArticleId></ArticleIdList></Reference><Reference><Citation>Frater JL, Zini G, d'Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol . 2020;42(Suppl 1) Suppl 1:11–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264622</ArticleId><ArticleId IdType="pubmed">32311826</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Urbistondo M, Gutiérrez-Rojas Á, Andrés A, Gutiérrez I, Escudero G, García S, et al. Severe lymphopenia as a predictor of COVID-19 mortality in immunosuppressed patients. 3595 J Clin Med . 2021;10(16)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8396991</ArticleId><ArticleId IdType="pubmed">34441891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>